Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $389,585.16 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Pushkal Garg also recently made the following trade(s):

• On Friday, February 14th, Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $255.17, for a total value of $398,320.37.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.00, for a total value of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Stock Down 0.2 %

NASDAQ ALNY traded down $0.41 on Friday, reaching $250.59. The company had a trading volume of 649,260 shares, compared to its average volume of 693,578. The firm has a market capitalization of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company's fifty day moving average is $254.04 and its 200-day moving average is $263.12.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $637,000. Focus Partners Advisor Solutions LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $203,000. Worldquant Millennium Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 156.6% during the 4th quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company's stock worth $35,341,000 after buying an additional 91,671 shares during the last quarter. Zurich Insurance Group Ltd FI acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $6,583,000. Finally, Vident Advisory LLC boosted its stake in shares of Alnylam Pharmaceuticals by 21.2% during the 4th quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company's stock worth $312,000 after buying an additional 232 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ALNY has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. Morgan Stanley boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $299.48.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.